Seventh Sense Biosystems raises $16 mln in Series B funding

Seventh Sense Biosystems, which develops blood collection and diagnostic platforms, has raised $16 million in Series B funding from a group of investors. New investors in the funding were the venture capital arm of Siemens Financial Services, Novartis and Laboratory Corporation of America Holdings. Existing investors Flagship Ventures and Polaris Partners also participated in the funding round.

VC-backed Editas Medicine hires CEO

Editas Medicine has hired Katrine S. Bosley as CEO. Previously, Bosley worked at Avila Therapeutics where she served as CEO. Based in Cambridge, Mass., Editas Medicine is a transformative genome editing firm. It is backed by Flagship Ventures, Polaris Partners, Third Rock Ventures and Partners Innovation Fund.


MassPRIM’s push into venture slowed last year: VCJ

The Massachusetts Pension Reserves Investment Management’s venture portfolio includes top name funds from Union Square Ventures, Spark Capital and Index Ventures, but after stepping on the gas early this decade, the board’s pace of commitments shifted to a lower gear last year, affiliate magazine Venture Capital Journal reports.

VC-backed Syros Pharmaceuticals hires new CFO

Syros Pharmaceuticals said Tuesday that it has hired Jorge Conde as chief financial officer and chief product officer. Previously, Conde was the co-founder and CFO of Knome. Based in Watertown, Mass., Syros is focused on treating cancer and other diseases. It is backed by Flagship Ventures and ARCH Venture Partners.

Seres Health pulls in $10 mln Series B

Seres Health said Monday that it has received $10 million in Series B funding. The investors included Flagship Ventures, Enso Ventures, Mayo Clinic and Alexandria Venture Investments. Based in Cambridge, Mass., Seres Health is a clinical stage biotherapeutic company focused on developing drugs that target the human microbiome.

Visterra closes Series A

Visterra, a developer of novel therapeutics to prevent and treat major infectious diseases, has secured $8.1 million in the final closing of its Series A financing round. This financing brings the total proceeds received to date from Series A to $34.2 million. Existing investors – Polaris Venture Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation and Omega Funds – participated in the financing, as well as members of management and employees.

Taris Biomedical Raises $12.5 Million

Taris Biomedical, a specialty pharmaceutical company developing therapies to treat bladder diseases, has raised a fresh $12.5 million in funding from its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners, and Third Rock Ventures. With the new funding, Taris, based in Lexington, Mass., has raised $49.8 million altogether.

With $270m Fund IV, Flagship’s Noubar Afeyan Is Still Bullish on Early Stage Healthcare

Common wisdom is that it’s an unusually tough time to raise capital for early-stage healthcare investing. But Cambridge, Mass.-based Flagship Ventures is demonstrating that it’s possible to buck the trend. This week, the 11-year-old firm announced it has raised $270 million for a fourth fund that will be dedicated principally to early-stage investing and in-house […]

Flagship Ventures Closes Fund IV with $270M

Cambridge, Mass.-based Flagship Ventures has closed its new fund, Flagship Ventures Fund IV L.P., with $270 million in commitments. The firm said it exceeded a $250 million target, and saw participation from pension funds, foundations, fund-of-funds, corporations and individuals. The early-stage investment firm was formed in 2000. It’s previous fund closed in 2007 with $235 million.

Acceleron Pharma Inks $30M

Cambridge, Mass.-based Acceleron Pharma Inc. has raised $30 million in financing. The company said that strategic partner Celgene contributed to the round, along with “all other existing investors.” Acceleron has raised capital from Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. The new funds will be used to expand the company’s clinical stage pipeline.

VC-backed Seventh Sense Inks $3.28M Grant

Seventh Sense Biosystems Inc., a Cambridge, Mass.-based developer of technology for decentralized diagnostic testing, has sealed a $3.28 million grant from the Bill & Melinda Gates Foundation. Formed in 2008, the company is backed by investors including Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.

Agios Pharmaceuticals Seals $78M Series C

Agios Pharmaceuticals, a Cambridge, Mass.-based developer of drugs to treat cancer, has sealed a whopping $78 million in fresh capital. The company did not disclose all investors in the Series C round, but said that publicly traded Celgene participated, as did existing backers ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Tangent Medical Closes $4.5M

Arboretum Ventures and Flagship Ventures co-led a $4.5 million Series A round for medical device startup Tangent Medical Technologies Inc. Osage Ventures and several undisclosed angel investors also contributed. Tim Petersen of Arboretum and Harry Wilcox of Flagship have joined Tangent’s board.

VC-Backed Quanterix Adds CEO

Martin Madaus has joined Quanterix Corp. as CEO. The company is a molecular diagnostics firm. Quanterix is backed by ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.

T2 Biosystems Seals $23M Series D

Lexington, Mass.-based T2 Biosystems has closed a $23 million Series D financing round led by new investor Aisling Capital. Return backers Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capital and WS Investments also contributed. The money will help with ongoing development and clinical trials of the company’s diagnostic technology.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget